



AMCP NEWS AND VIEWS

FEBRUARY 2018

HOME
CONTACT US
TWITTER
FACEBOOK
LINKEDIN

AMCP members are committed to providing the best available pharmaceutical care for patients.

Visit www.amcp.org to learn more about the Academy of Managed Care Pharmacy and the opportunities we can offer.

IN THIS ISSUE

[PIE Act Is Now Before the Full E&C Committee](#)
[CEO Blog: PIE Act Addresses Lag Between FDA Approval, Patient Access](#)
[VIDEO: Academy Urges Passage of PIE Act](#)
[Feedback: Education Knowledge Gap Assessment Survey](#)
[Experts Gather to Discuss Biosimilars, Consider BBCIC Research](#)
[Lockhart Takes the Helm of BBCIC as New Program Director](#)
[AMCP Student Pharmacist Chapter Spotlight: U. of Kentucky](#)
[AMCP Members the News](#)
[AMCP Annual Meeting's Pre-Meeting Events!](#)
[Non-Commercial, Industry-Supported Satellite Symposia](#)
[AMCP Corporate Training Focuses on Value-Based Health Care](#)
[Meeting Rooms for Corporate Member Exhibitors and Sponsors](#)
[AMCP Learn Offers CPE Sessions From Past Conferences and Meetings](#)
[AMCP eDossier System Provides Resources for Cancer Product Reviews](#)

LOOKING AHEAD

How can Payers Cope with Consequences of Accelerated Approval – U.S. vs. Global Experience

Thursday, Feb. 22, 2pm EST

[AMCP Members and Non-Members - Free](#)

Implications for Managed Care Pharmacy from the 2019 Medicare Part D Call Letter and Star Ratings Release

Tuesday, February 27, 2018, 2-3pm EST

[AMCP Members - Free](#) [AMCP Non-Members - \\$69](#)

Patient Reported Outcomes: The Missing Link to Defining Value - Proceedings from the AMCP Partnership Forum

Wednesday, April 11, 2pm EDT

[AMCP Members - Free](#) [AMCP Non-Members - \\$69](#)

SHINGRIX NOW APPROVED

Cover SHINGRIX today and expand vaccine access for your members.



Trademarks owned or licensed by GSK.
©2017 GSK or licensor. 822517R0 October 2017

SHINGRIXHCP.COM



SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)



House Subcommittee on Health Approves PIE Act (H.R. 2026); Bill Is Now Before the Full E&C Committee

In a significant milestone for an AMCP-supported bill, the House Energy and Commerce (E&C) Committee's Subcommittee on Health last month approved [H.R. 2026](#), the "Pharmaceutical Information Exchange (PIE) Act of 2018." The bill is now before the full E&C Committee, where a vote is expected this month.

Sponsored by Rep. Brett Guthrie (R-KY), the PIE Act would allow biopharmaceutical manufacturers to proactively share certain clinical and economic information with decision makers on emerging therapies in advance of FDA approval, an area currently restricted by federal law and FDA regulation.



AMCP has been a leading advocate for this legislation. Read AMCP CEO Susan A. Cantrell, RPh, CAE, [Jan. 17 letter](#) to Subcommittee Chairman Michael C. Burgess and Ranking Member Gene Green. For more information, [visit here](#).

(image: Members of AMCP's legislative affairs team attend Jan. 17 markup of H.R. 2026. From left: Soumi Saha, Lauren Lyles, Zain Madhani and Elizabeth Brisley)



PIE Act Addresses Lag Between FDA Approval and Patient Access; Cantrell Makes Case for H.R. 2026 in Op-Ed in *The Hill*

AMCP CEO Cantrell describes The PIE Act's implications for patients in a new [op-ed in The Hill newspaper](#):

The FDA approved [46 novel drugs in 2017](#), a 21-year high. However, it could take as long as six months for some of these groundbreaking medicines to reach patients, as pharmaceutical review committees work their way through complex clinical information to determine how, when, and why a new drug should be prescribed. The way things stand now, the insurers and pharmacy benefits managers (PBMs) that set copayments, premiums, and reimbursement rates do not receive reliable data about a new treatment until it is approved by the FDA. But it can take months to assess that information and establish appropriate prescribing standards, meet state health insurance rate filings, fulfill Medicare and Medicaid requirements, and negotiate contracts with health care purchasers.

Read Cantrell's full op-ed at bit.ly/2DQpuIZ

VIDEO: Academy Urges Passage of PIE Act, Bill Is



Before E&C Committee

AMCP has been leading a broad health care stakeholder advocacy effort to encourage House passage of H.R. 2026, the Pharmaceutical Information Act (PIE Act).

In a new video, Soumi Saha, PharmD, JD, AMCP Director of Pharmacy & Regulatory Affairs, describes the PIE Act and issues a call for action.

Watch the [video here](#).





AMCP Wants Your Feedback: Please Take Education Knowledge Gap Assessment Survey

The Academy needs your help in planning education programming for the coming year. This survey is designed to provide feedback on your specific educational needs in a variety of areas specific to managed care pharmacy. Please be sure to complete the survey by **Sunday, Feb. 11** and provide your thoughts in the free text boxes. We read every comment! Thank you in advance for your valuable input. To start the survey, please [click here](#).



Experts Gather at AMCP Headquarters to Discuss Biosimilars, Consider BBCIC Research Priorities






The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) held its second annual workshop on Feb. 6 to review BBCIC's current research activities and consider 2018 research methods and strategic initiatives.

The event, held at AMCP headquarters in Alexandria, Va., also included discussions on the U.S. biosimilar landscape; the FDA Sentinel Project; opportunities to expand BBCIC data capabilities; the 21st Century Cures Act; and the FDA framework for regulatory use of real-world evidence. The more than 30 participants included representatives from health plans, the biopharmaceutical industry, biomedical research institutions and the FDA.

“The annual workshop offers BBCIC’s organizations and stakeholders a chance to take stock of the biosimilars marketplace and map out a strategy for the coming year,” said BBCIC’s new Program Director Cate Lockhart, PharmD, PhD. “We have established a strong research framework for conducting surveillance of biosimilar products, and we’re ready to go once utilization increases among providers and patients.”

The BBCIC was convened by AMCP in 2015 to address expected uncertainties in the minds of prescribers, patients and others about the safety and effectiveness of biosimilars through a science-driven, transparent approach that leverages existing distributed research network resources. Visit www.bbic.org/.

(Images: from top, AMCP CEO Cantrell welcomes members of the BBCIC; Cantrell (left) poses with former BBCIC Program Director Bernadette Eichelberger (center) and new BBCIC Program Director Cate Lockhart; BBCIC Chief Science Officer Charlie Barr addresses gathering)



Cate Lockhart Takes the Helm of BBCIC as New Program Director

The BBCIC is pleased to announce that Cate Lockhart, PharmD, PhD, has been appointed Program Director. In this role, she will lead the development and growth of the multi-stakeholder research collaborative. Lockhart replaces previous Program Director Bernadette Eichelberger, who retired last year.

Before coming to BBCIC, Lockhart was the Health Economics and Outcomes Research expert at Omeros, a small biopharmaceutical company based in Seattle, Wash. She also served as Research Team Coordinator for the BBCIC for over a year, working directly with the former Program Director to support research activities conducted throughout the past year. Prior to working in the pharmaceutical industry, Lockhart served as a consultant preparing formulary dossiers on behalf of drug and device manufacturers.



“Cate takes the helm of BBCIC at a crucial time in the evolution of biosimilars entering the U.S. market,” says AMCP CEO Susan A. Cantrell, RPh, CAE. “A handful of biosimilars have been approved, but many more are poised to enter the market soon, making the task of BBCIC more important than ever. Cate brings a combination of clinical, economic and scientific expertise that will allow BBCIC to advance its mission.” [Read more.](#)

AMCP Student Pharmacist Chapter Spotlight: University of Kentucky



The University of Kentucky College of Pharmacy is excited to have established an AMCP student chapter this past fall. One of the main goals of our chapter this year has been to compete in the P&T Competition. Four P3 students from UK have taken on this challenge and have been working diligently to perfect their P&T proposal. While competing as a new chapter has its obstacles, the faculty at UK have been outstanding in assisting our P&T team with whatever questions they might have in regards to the competition material. Additionally, our team has been able to utilize the resources that AMCP provides to the P&T competitors, including the training webinars and the P&T 101 documents. These resources were extremely useful to our team since our chapter is new to the competition. Overall, the UK College of Pharmacy AMCP student chapter is thrilled to have the chance to compete in the P&T competition for the first time. If other new chapters are interested in competing in the P&T competition next year, our chapter recommends to start the process by utilizing the AMCP P&T resources via the following link: www.amcp.org/amcp-foundation/PT/



AMCP Members the the News

AMCP President-Elect **Mitzi M. Wasik**, PharmD, BCPS, FAMCP, FCCP, has been appointed Senior Director of Patient Safety and Quality at Aetna. Previously she served as Lead Strategy Business Consultant for the Southeast market for Medicare at Aetna. In addition, Mitzi led the clinical pharmacy team responsible for clinical pharmacy programs that supported the CMS Stars Measures, including readmissions, MTM, SNP, and the Part D Patient Safety Measures.



EDITOR'S NOTE: N&Vs wants to share your good news: If you recently moved into a new position or received a professional award or recognition, please forward the notice to nlearner@amcp.org.



Start AMCP Annual Meeting Learning Early with Pre-Meeting Events!

Begin your Annual Meeting experience on April 23 with a series of pre-Meeting programs covering some of the hottest topics today! Choose from:

- [Specialty Connect 2018](#) is designed for industry leaders, experts and managed care pharmacists operating in the fast-growing specialty sector. This year's focus is on Hemophilia, a disease state with breakthrough therapeutics, but challenging management issues. Presentations include: the Present and Future of Hemophilia Treatment; Managing Patients with Hemophilia: A Payer's Perspective; Gene Therapy for Hemophilia: Hope for a Cure?; and the program will close with a panel discussion on managing hemophilia.
- [Residency Program Design and Conduct \(RPDC\)](#) - In this workshop, attendees will review accreditation standards for the design and conduct of a PGY1 Managed Care pharmacy residency program, including requirements related to program purpose, competency areas, goals and objectives, program structure, learning experiences, orientation, use of preceptor roles, evaluation, resident development plans, and continuous residency program improvement. Attendees may bring materials from their program for review during the workshop.
- [Comparative Effectiveness Research Certificate Program](#) - CER is the key to efficiently and effectively assessing the value of new treatments using multiple types of studies to inform medical policy and decision-making. This program is the final interactive peer workshop following five online modules. Please note: you must register for this program [here](#) by March 12.



Earn an Additional Nine CPE Credits at Annual Meeting in Non-Commercial, Industry-Supported Satellite Symposia

Satellite Symposia offered in conjunction with the Annual Meeting can extend the educational experience of meeting attendees and provide continuing pharmacy education credit (CPE), continuing medical education credit (CME), continuing nursing education credit (CNE) or all three. Topics include multiple sclerosis, hemophilia, asthma, atopic dermatitis, psoriatic disease, non-small-cell lung cancer, multiple myeloma and migraine. All symposia will be held at the Boston Convention & Exhibition Center in Boston. For more information, [click here](#).



AMCP Corporate Training Focuses on Delivering Value in Value-Based Health Care

AMCP's new [Corporate Training](#) program, "Engaging Your Customers in a Value-Based Health Care Market," provides attendees with insights into one of today's hottest health care trends, and identifies opportunities for your organization to deliver value. Designed for account managers, marketers, medical science liaisons and others, the program takes place April 23 and 24 in conjunction with the AMCP Annual Meeting in Boston. Participants will have the chance to interact with executives of health plans, ACOs, IDNs, PBMs and top consultants as they examine the issue of value-based health care at the intersection of managed care and integrated delivery systems. Registration for the Annual Meeting is included in the fees for this program. Click to [register](#) or learn more at www.amcpcorporatetraining.org.

NEW! Meeting Rooms Are Available for Corporate Member Exhibitors and



Sponsors at Annual Meeting

AMCP is offering a new, convenient way for its Corporate Members who are exhibiting or sponsoring at the 2018 Annual Meeting to meet with managed care representatives and other partners attending the April 23-26 event in Boston. Members will be able to conduct client meetings in private rooms adjacent to the Exposition Area. The modular, hard-walled rooms are available in two sizes: a 10x10 office with carpet, table and four chairs; and a 10x20 office with carpet, table, and four chairs. Access hours are: Tuesday, April 24, 6pm-7:30pm; Wednesday, April 25, 7am-6pm, and Thursday, April 26, 7am-11am. For more information, pricing and to reserve a space, contact Joshua Maze at 703-684-2619 or jmaze@amcp.org. Access the [agreement here](#).



Members Can Take Advantage of AMCP Learn to Access CPE Sessions From Past Conferences and Meetings

AMCP members can tap a wealth of resources on [AMCP Learn](#) — *many of them free as part of your membership* — to advance your professional knowledge and earn continuing pharmacy education (CPE) credits. Take advantage of this AMCP member benefit to access sessions from recent Annual Meetings and Nexus conferences. Offerings include:



THE BEST OF NEXUS 2017: AMCP has compiled a list of the best sessions from AMCP Nexus 2017 in Dallas, Texas. [Learn more](#)



SESSIONS FROM AMCP ANNUAL 2017!: A selection of home study activities adapted from sessions presented at the Annual Meeting 2017 in Denver. Click on [Main Catalog](#) and sort by “Newest” to see the latest offerings.



SESSIONS FROM AMCP NEXUS 2016!: A selection of home study activities adapted from sessions presented at Nexus 2016 in National Harbor, Maryland. Click on [Main Catalog](#) and sort by “Newest” to see the latest offerings.



AMCP eDossier System Provides Resources for Cancer Product Reviews

American Cancer Society estimates that over 15.5 million people alive in the US have a history of cancer and projects that this number will continue to increase. To address this issue, emerging cancer products are in development, with

pipeline drug trends that include breakthrough therapies, targeted therapies, oral cancer drugs and biosimilars. For US payer formulary reviews, product resources for over 200 pipeline and FDA-approved cancer drugs are easily accessible via the AMCP eDossier System @ FormularyDecisions.com: <https://amcp.edossiers.com> To learn how global payers manage accelerated approval for cancer drugs and other therapies and implications for US payers, join the [AMCP webinar](#) on Feb. 22 at 2-3pm ET This webinar will review international practices, identify useful resources and include real life commentary from diverse US plans.

Academy of Managed Care Pharmacy

675 North Washington Street, Suite 220, Alexandria, VA 22314
703.684.2600 | www.amcp.org

Editor Neal Learner, Media Relations and Editorial Director

Inquiries or submissions for publication should be directed to newsletter@amcp.org



[Manage My Emails](#)